title: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
abstract: OBJECTIVE
  To assess antitumor response and time to progression (TTP) with docetaxel compared with doxorubicin in first-line treatment of advanced and/or metastatic soft tissue sarcoma.
  
  
  METHODS
  Patients with measurable soft tissue sarcoma lesions and adequate bone marrow, liver, and renal function were entered onto the study. They were randomized to either docetaxel 100 mg/m(2) given as a 1-hour intravenous infusion every 3 weeks or doxorubicin 75 mg/m(2) given as a bolus injection every 3 weeks. A maximum of seven cycles of treatment were scheduled. The study was designed as a randomized phase III study evaluating TTP by log-rank model. There was a clause for premature closure of the trial if fewer than five responses were observed among the first 25 assessable patients in the docetaxel treatment arm.
  
  
  RESULTS
  Eighty-six patients were entered onto the study; 85 were assessable for toxicity and 83 for response. The rate of severe granulocytopenia was not significantly different between the two arms. Nausea (P =.001), vomiting (P <.001), and stomatitis (P =.005) were more common with doxorubicin therapy, whereas neurotoxicity was more frequent with docetaxel treatment. The response rate to doxorubicin therapy was 30% (95% confidence interval, 17% to 46%), whereas no responses to docetaxel therapy were seen (P <.001). In view of this, the trial was closed prematurely and the phase III study part was not conducted.
  
  
  CONCLUSIONS
  Docetaxel is inactive in soft tissue sarcomas and cannot be recommended for further use in treatment of this disease.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute, and University Hospital Rotterdam, Nijmegen, the Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: S M
authors.initials: SM
authors.lastname: Lee
authors.forename: W
authors.initials: W
authors.lastname: Ruka
authors.forename: J
authors.initials: J
authors.lastname: Buesa
authors.forename: R
authors.initials: R
authors.lastname: Coleman
authors.forename: R
authors.initials: R
authors.lastname: van Hoessel
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
authors.forename: E D
authors.initials: ED
authors.lastname: di Paola
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
authors.forename: D
authors.initials: D
authors.lastname: Tonelli
authors.forename: I R
authors.initials: IR
authors.lastname: Judson
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use; D018592:Cross-Over Studies; D018450:Disease Progression; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D016019:Survival Analysis; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel